Matt Miksic
Stock Analyst at Barclays
(3.71)
# 781
Out of 4,996 analysts
295
Total ratings
59.66%
Success rate
3.98%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SENS Senseonics Holdings | Initiates: Overweight | $1.5 | $0.46 | +226.09% | 1 | Aug 27, 2025 | |
| HUMA Humacyte | Initiates: Overweight | $3.5 | $1.73 | +102.31% | 1 | Aug 27, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $55 → $58 | $53.44 | +8.53% | 8 | Aug 21, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $266 → $300 | $318.00 | -5.66% | 9 | Aug 21, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $53 → $51 | $12.00 | +325.00% | 7 | Aug 8, 2025 | |
| BAX Baxter International | Maintains: Overweight | $41 → $36 | $21.98 | +63.79% | 22 | Aug 4, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $21 → $22 | $15.02 | +46.47% | 3 | Aug 4, 2025 | |
| INMD InMode | Maintains: Overweight | $24 → $21 | $14.90 | +40.94% | 14 | Jul 30, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $93 → $98 | $67.10 | +46.05% | 7 | Jul 30, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $90 → $95 | $76.25 | +24.59% | 29 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $133 | $98.18 | +35.47% | 18 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $9 → $19 | $18.91 | +0.48% | 8 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $176 | $179.71 | -2.06% | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $19 → $16 | $14.50 | +10.34% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $184.60 | +30.55% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $2.40 | +400.00% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $441.12 | +43.95% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $158 → $159 | $133.55 | +19.06% | 29 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $55.70 | +84.92% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $98.24 | +14.01% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $369.02 | +20.05% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.29 | +412.82% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $94.22 | +15.69% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $73.92 | +29.87% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $66.04 | +51.42% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $126.19 | +231.25% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $15.82 | +76.99% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $12.50 | +436.00% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $5.46 | +8,691.21% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $13.20 | +559.09% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.10 | +509.76% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.94 | +29.68% | 1 | Dec 12, 2016 |
Senseonics Holdings
Aug 27, 2025
Initiates: Overweight
Price Target: $1.5
Current: $0.46
Upside: +226.09%
Humacyte
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.73
Upside: +102.31%
LivaNova
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $53.44
Upside: +8.53%
Insulet
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $266 → $300
Current: $318.00
Upside: -5.66%
Tandem Diabetes Care
Aug 8, 2025
Maintains: Overweight
Price Target: $53 → $51
Current: $12.00
Upside: +325.00%
Baxter International
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $21.98
Upside: +63.79%
Alphatec Holdings
Aug 4, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $15.02
Upside: +46.47%
InMode
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.90
Upside: +40.94%
DexCom
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $93 → $98
Current: $67.10
Upside: +46.05%
Edwards Lifesciences
Jul 25, 2025
Maintains: Overweight
Price Target: $90 → $95
Current: $76.25
Upside: +24.59%
Jul 24, 2025
Maintains: Overweight
Price Target: $125 → $133
Current: $98.18
Upside: +35.47%
Jul 22, 2025
Upgrades: Equal-Weight
Price Target: $9 → $19
Current: $18.91
Upside: +0.48%
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $165 → $176
Current: $179.71
Upside: -2.06%
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $14.50
Upside: +10.34%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $184.60
Upside: +30.55%
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.40
Upside: +400.00%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $441.12
Upside: +43.95%
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $133.55
Upside: +19.06%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $55.70
Upside: +84.92%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $98.24
Upside: +14.01%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $369.02
Upside: +20.05%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.29
Upside: +412.82%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $94.22
Upside: +15.69%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $73.92
Upside: +29.87%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $66.04
Upside: +51.42%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $126.19
Upside: +231.25%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $15.82
Upside: +76.99%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $12.50
Upside: +436.00%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $5.46
Upside: +8,691.21%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $13.20
Upside: +559.09%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.10
Upside: +509.76%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.94
Upside: +29.68%